JAGUAR HEALTH, INC. Proceeds from Issuance of Debt
JAGUAR HEALTH, INC. (JAGX) reported Proceeds from Issuance of Debt of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2023-03-24
- JAGUAR HEALTH, INC. proceeds from issuance of debt for the quarter ending 2021-12-31 was $0.00.
- JAGUAR HEALTH, INC. proceeds from issuance of debt for fiscal 2021 was $10.97M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $10.97M 10-K · filed 2023-03-24 | |
| 2021-09-30 | $10.97M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |